Onvansertib
- Generic Name
- Onvansertib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C24H27F3N8O3
- CAS Number
- 1034616-18-6
- Unique Ingredient Identifier
- 67RM91WDHQ
- Background
Onvansertib is under investigation in clinical trial NCT03303339 (Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML).).
- Associated Conditions
- -
- Associated Therapies
- -
Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms
Phase 1
Recruiting
- Conditions
- Recurrent Chronic Myelomonocytic LeukemiaRefractory Chronic Myelomonocytic LeukemiaRecurrent Atypical Chronic Myeloid LeukemiaMyelodysplastic/Myeloproliferative Neoplasm, Not Otherwise SpecifiedRecurrent Myelodysplastic/Myeloproliferative NeoplasmRefractory Myelodysplastic/Myeloproliferative Neoplasm
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow Aspiration and BiopsyDrug: OnvansertibProcedure: Ultrasound Imaging
- First Posted Date
- 2022-09-22
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 25
- Registration Number
- NCT05549661
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Onvansertib in Combination with Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants with Metastatic Pancreatic Ductal Adenocarcinoma
Phase 2
Completed
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2021-02-12
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Cardiff Oncology
- Target Recruit Count
- 43
- Registration Number
- NCT04752696
- Locations
- 🇺🇸
Mayo Clinic Jacksonville, Jacksonville, Florida, United States
🇺🇸Inova Schar Cancer Institute, Fairfax, Virginia, United States
🇺🇸Mayo Clinic Rochester, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath